Intravitreal bevacizumab for neovascular age-related macular degeneration: twelve months of follow up

Autor: R. Bouraoui, L. El Matri, N. Ben Youssef, K. Baklouti, Fedra Kort, H Landoulsi, R. Limaiem
Rok vydání: 2009
Předmět:
Zdroj: Acta Ophthalmologica. 87
ISSN: 1755-3768
1755-375X
Popis: Purpose To evaluate the efficacy and safety of intravitreal bevacizumab for managing choroidal neovascularization (CNV) due to age-related macular degeneration (AMD) at one-year of follow-up. Methods A retrospective review of all patients treated with intravitreal bevacizumab (1.25mg in 0.05ml) for subfoveal or juxtafoveal CNV from AMD between June 2006 and December 2008. The files were reviewed for background data, visual acuity, fluorescein angiography, central retinal thickness and complications. Patients received injections every 4 to 6 weeks until resolution of CNV activity. Results A total of 72 eyes of 67 patients were treated. Mean follow-up was 14.1 months (range 11 to 16 months). Twenty seven percent of patients had undergone previous PDT treatment for CNV. The mean number of injections was 2.9. The mean best corrected visual acuity was 1.06 logMAR (range 2 – 0.1 logMAR) at baseline and improved to 0.9 logMAR (range 2- 0.2 logMAR) at the last visit. The mean central retinal thickness was 404µm (range 191 – 1070 microns) at baseline and decreased to 279.9µm (range 140- 620µm) at 14-months follow-up. Statistically significant differences were found in visual acuity (p=0.044) and central retinal thickness (p=0.01) before and after intravitreal injections. No significant ocular or systemic side effects were observed. Conclusion Our results suggest that intravitreal bevacizumab is well tolerated and is associated with improvement in visual acuity and decrease in retinal thickness at 12 months of follow-up. Further controlled, prospective and long term evaluation of this treatment is warranted.
Databáze: OpenAIRE
Externí odkaz: